The University of Chicago Header Logo

Connection

Mary Rinella to Adult

Back to Details
This is a "connection" page, showing publications Mary Rinella has written about Adult.
Mary Rinella
Connection Strength
0.686
Adult
  1. Accuracy of the FIB-4 and LiverRisk score for use in primary risk assessment for liver fibrosis, and variation by age. Dig Liver Dis. 2026 07; 58(7):935-942.
    View in: PubMed
    Score: 0.058
  2. Variance Between Clinical Guidance and Real-World Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):374-376.e3.
    View in: PubMed
    Score: 0.051
  3. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey. Ann Med. 2023 12; 55(1):2211349.
    View in: PubMed
    Score: 0.049
  4. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548.
    View in: PubMed
    Score: 0.042
  5. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
    View in: PubMed
    Score: 0.042
  6. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019 10; 70(4):1424-1436.
    View in: PubMed
    Score: 0.036
  7. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019 04; 70(4):735-744.
    View in: PubMed
    Score: 0.035
  8. Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis. Obstet Gynecol. 2017 06; 129(6):1118-1123.
    View in: PubMed
    Score: 0.031
  9. Primary biliary cirrhosis. Ann Hepatol. 2006 Jul-Sep; 5(3):198-200.
    View in: PubMed
    Score: 0.015
  10. The Relentless Progression of Metabolic Dysfunction-associated Steatotic Liver Disease in Liver Transplantation in Spain. Transplantation. 2026 Feb 01; 110(2):e444-e452.
    View in: PubMed
    Score: 0.014
  11. Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Aliment Pharmacol Ther. 2025 Dec; 62(11-12):1089-1099.
    View in: PubMed
    Score: 0.014
  12. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 05; 392(21):2089-2099.
    View in: PubMed
    Score: 0.013
  13. Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis. J Gastroenterol. 2025 07; 60(7):891-904.
    View in: PubMed
    Score: 0.013
  14. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 06; 11(1):14.
    View in: PubMed
    Score: 0.013
  15. Risk Stratification for Chronic Kidney Disease After Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Cirrhosis: Results From the NailMASH Consortium. Transplantation. 2025 03 01; 109(3):484-495.
    View in: PubMed
    Score: 0.013
  16. Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 12; 60(11-12):1525-1533.
    View in: PubMed
    Score: 0.013
  17. Body composition and muscle composition phenotypes in patients on waitlist and shortly after liver transplant - results from a pilot study. BMC Gastroenterol. 2024 Oct 09; 24(1):356.
    View in: PubMed
    Score: 0.013
  18. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.012
  19. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Liver Transpl. 2003 Aug; 9(8):851-6.
    View in: PubMed
    Score: 0.012
  20. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. J Hepatol. 2023 11; 79(5):1110-1120.
    View in: PubMed
    Score: 0.012
  21. Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis. Gastrointest Endosc. 2003 Jul; 58(1):122-7.
    View in: PubMed
    Score: 0.012
  22. Liver biopsy in living donors. Liver Transpl. 2002 Dec; 8(12):1123-5.
    View in: PubMed
    Score: 0.011
  23. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
    View in: PubMed
    Score: 0.010
  24. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol. 2022 09; 20(9):2050-2058.e12.
    View in: PubMed
    Score: 0.010
  25. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl. 2001 May; 7(5):409-14.
    View in: PubMed
    Score: 0.010
  26. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 07; 72(1):58-71.
    View in: PubMed
    Score: 0.010
  27. Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. J Am Heart Assoc. 2020 02 18; 9(4):e014279.
    View in: PubMed
    Score: 0.009
  28. Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. J Gen Intern Med. 2019 12; 34(12):2772-2778.
    View in: PubMed
    Score: 0.009
  29. Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. Transplant Proc. 2019 Jul - Aug; 51(6):1895-1901.
    View in: PubMed
    Score: 0.009
  30. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2019 05; 114(5):758-763.
    View in: PubMed
    Score: 0.009
  31. Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. Gastroenterology. 2019 08; 157(2):472-480.e5.
    View in: PubMed
    Score: 0.009
  32. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. Liver Int. 2019 05; 39(5):933-940.
    View in: PubMed
    Score: 0.009
  33. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018 06; 47(12):1639-1651.
    View in: PubMed
    Score: 0.008
  34. Twenty-five-year trajectories of insulin resistance and pancreatic ß-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int. 2018 11; 38(11):2069-2081.
    View in: PubMed
    Score: 0.008
  35. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018 08; 155(2):422-430.e1.
    View in: PubMed
    Score: 0.008
  36. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018 03 24; 391(10126):1174-1185.
    View in: PubMed
    Score: 0.008
  37. Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. Transplantation. 2017 12; 101(12):2873-2882.
    View in: PubMed
    Score: 0.008
  38. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int. 2018 04; 38(4):706-714.
    View in: PubMed
    Score: 0.008
  39. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 01; 67(1):328-357.
    View in: PubMed
    Score: 0.008
  40. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2017 05; 112(5):755-762.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.